| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 08/06/2002 | US6429205 Anticoagulants |
| 08/06/2002 | US6429203 Farnesyl-protein transferase inhibitors |
| 08/06/2002 | US6429195 Aqueous prolonged release formulation |
| 08/06/2002 | US6429192 Separating mannan-binding lectin (mbl) by affinity chromatography on non-conjugated cross-linked polysaccharide matrix and performing a validated virus reduction step |
| 08/06/2002 | US6429188 Vasoactive intestinal peptide and peptide activating hypofissiary adenylate cyclase; inhibiting production of tumor necrosis factor and interleukin 6; amino acid seq id no:1, 2 and 3 |
| 08/06/2002 | US6428977 Transforming growth factor-beta (tgf-beta); nucleic acid; polypeptide promotes the formation of ventral mesoderm in xenopus animal pole explants; use promoting osteogenesis for example |
| 08/06/2002 | US6428950 Culturing glial cells which express apolipoprotein e at known level, contacting cells with compound to be tested, comparing apolipoprotein e expression of glial cells in contact with compound with apolipoprotein e expression in control culture |
| 08/06/2002 | US6428812 Process for producing granules containing angiotensin-converting enzyme inhibiting peptides |
| 08/06/2002 | CA2236707C Fused tropane-derivatives, their preparation and use |
| 08/06/2002 | CA2144327C Transcutaneous in vivo activation of photosensitive agents in blood |
| 08/06/2002 | CA2076060C Compounds named the adenophostins, their preparation and their therapeutic use |
| 08/02/2002 | CA2369789A1 Combination treatment for depression |
| 08/01/2002 | WO2002059612A2 Animal model and cell-line expressing modified chlorine channel |
| 08/01/2002 | WO2002059323A2 Aminoacyl trna synthetases |
| 08/01/2002 | WO2002059312A2 Cell adhesion proteins |
| 08/01/2002 | WO2002059308A2 Method of diagnosing and treating cartilage disorders |
| 08/01/2002 | WO2002059302A2 Regulation of human serotonin-like g protein-coupled receptor |
| 08/01/2002 | WO2002059295A1 Novel serine protease mp493 |
| 08/01/2002 | WO2002059293A2 Process and compositions for peptide, protein and peptidomimetic synthesis |
| 08/01/2002 | WO2002059289A1 Use of microbial hyaluronate lyase for softening connective tissue |
| 08/01/2002 | WO2002059283A2 Nucleic acid modification enzymes |
| 08/01/2002 | WO2002059267A2 Constitutively desensitized g protein-coupled receptors |
| 08/01/2002 | WO2002059153A2 Anticoagulants and their uses |
| 08/01/2002 | WO2002059150A2 Materials and methods relating to protein aggregation in neurodegenerative disease |
| 08/01/2002 | WO2002059146A2 Peptides having affinity for the gp120 viral protein and use thereof |
| 08/01/2002 | WO2002059141A1 Peptide derivatives |
| 08/01/2002 | WO2002059131A1 Formulation of boronic acid compounds |
| 08/01/2002 | WO2002059130A1 Formulation of boronic acid compounds |
| 08/01/2002 | WO2002059129A2 Substituted tetracyclic pyridoindoles as serotonin agonists and antagonists |
| 08/01/2002 | WO2002059127A2 Pyrazinoquinoxaline derivatives as serotonin agonists and antagonists |
| 08/01/2002 | WO2002059126A1 Process for the preparation of a pyrazolo[4,3-d]pyrimidine derivative |
| 08/01/2002 | WO2002059125A1 Cyclin dependent kinase inhibiting purine derivatives |
| 08/01/2002 | WO2002059122A1 ANTI-CANCER 2,3-DIHYDRO-1H-PYRROLO[3,2-f]QUINOLINE COMPLEXES OF COBALT AND CHROMIUM |
| 08/01/2002 | WO2002059117A1 Piperazine- and piperidine-derivatives as melanocortin receptor agonists |
| 08/01/2002 | WO2002059116A2 Antimicrobial quinolone derivatives and use of the same to treat bacterial infections |
| 08/01/2002 | WO2002059113A1 2h-1-benzopyran derivatives, processes for their preparation and pharmaceutical compositions thereof |
| 08/01/2002 | WO2002059112A2 Pyrazole compounds useful as protein kinase inhibitors |
| 08/01/2002 | WO2002059111A2 Pyrazole compounds useful as protein kinase inhibitors |
| 08/01/2002 | WO2002059109A2 Naphthostyril derivatives and their use as inhibitors of cyclin- dependent kinases |
| 08/01/2002 | WO2002059108A1 Melanocortin receptor agonists |
| 08/01/2002 | WO2002059106A1 Isoindole-imide compounds, compositions, and uses thereof |
| 08/01/2002 | WO2002059105A1 Styrene derivatives and process for production thereof |
| 08/01/2002 | WO2002059100A1 Halogen compounds having thrombopoietin receptor agonism |
| 08/01/2002 | WO2002059098A1 Thiazole and oxazole derivatives as activators of human peroxisome proliferator activated receptors |
| 08/01/2002 | WO2002059092A1 Process for the preparation of (3-cyano-1h-indol-7-yl)(4-(4-fluorophenethyl)piperazin-1-yl)-methanone and salts thereof |
| 08/01/2002 | WO2002059088A1 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands |
| 08/01/2002 | WO2002059083A2 Novel compounds |
| 08/01/2002 | WO2002059082A2 Aryl and aminoaryl substituted serotonin receptor agonist and antagonist ligands |
| 08/01/2002 | WO2002059080A2 Trisubstituted carbocyclic cyclophilin binding compounds and their use |
| 08/01/2002 | WO2002059074A1 Benzylamine analogue |
| 08/01/2002 | WO2002058737A2 Multivalent meningococcal polysaccharide-protein conjugate vaccine |
| 08/01/2002 | WO2002058734A2 Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions |
| 08/01/2002 | WO2002058733A2 Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications |
| 08/01/2002 | WO2002058731A2 Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions |
| 08/01/2002 | WO2002058730A2 Compositions for treatment of ocular neovascularization |
| 08/01/2002 | WO2002058729A2 Methods of inducing organ transplant tolerance and correcting hemoglobinopathies |
| 08/01/2002 | WO2002058723A2 Chemokines as adjuvants of immune response |
| 08/01/2002 | WO2002058721A1 Trem-1 splice variant for use in modifying immune responses |
| 08/01/2002 | WO2002058709A1 Methods for inhibiting proliferation of astrocytes and astrocytic tumor cells and uses thereof |
| 08/01/2002 | WO2002058706A2 Combination of an estrogen and an androgen for treating hormonal deficiencies in women undergoing estrogen replacement therapy |
| 08/01/2002 | WO2002058701A1 Pharmaceutical dosage forms of epothilones for oral administration |
| 08/01/2002 | WO2002058700A1 Methods of administering epothilone analogs for the treatment of cancer |
| 08/01/2002 | WO2002058699A1 Pharmaceutical forms of epothilones for oral administration |
| 08/01/2002 | WO2002058698A2 Malonyl-coa decarboxylase inhibitors useful as metabolic modulators |
| 08/01/2002 | WO2002058696A2 The use of substituted azetidinone compounds for the treatment of sitosterolemia |
| 08/01/2002 | WO2002058692A2 Halogenated composition, method for preparing same and uses thereof |
| 08/01/2002 | WO2002058690A2 Methods for the treatment of diseases using malonyl-coa decarbox ylase inhibitors |
| 08/01/2002 | WO2002058685A2 Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications |
| 08/01/2002 | WO2002058684A2 Combinations of drugs (e.g., chlorpromazine and pentamidine) for the treatment of neoplastic disorders |
| 08/01/2002 | WO2002058677A1 New film coating |
| 08/01/2002 | WO2002058670A1 Local anesthetic, and method of use |
| 08/01/2002 | WO2002058636A2 Novel cannabimimetic ligands |
| 08/01/2002 | WO2002058623A2 Inhibitors of spermidine synthase for the treatment of osteoarthritis and cartilage rehabilitation |
| 08/01/2002 | WO2002058546A2 Methods for screening for substances which inhibit fp prostanoid receptor |
| 08/01/2002 | WO2002058532A2 Method for identifying ligands to lxr-receptor that stimulates pre-adipocyte differentiation and formulations thereof |
| 08/01/2002 | WO2002058450A2 Regulation of cell growth by muc1 |
| 08/01/2002 | WO2002051424A8 Drugs against articular failure |
| 08/01/2002 | WO2002045749A3 Methods for stimulating nervous system regeneration and repair by inhibition phosphodiesterase type 4 |
| 08/01/2002 | WO2002042278A3 Imidazole and benzimidazole caspase inhibitors and uses thereof |
| 08/01/2002 | WO2002040048A3 Recombined anti-gpiib/iiia antibodies used for inhibiting angiogenesis |
| 08/01/2002 | WO2002038646A3 Novel polyesters, method for producing the same and depot medicaments produced from these polyesters |
| 08/01/2002 | WO2002036761A9 Compositions and methods for the diagnosis of cancer |
| 08/01/2002 | WO2002030461A3 Methods for treating disorders of the female reproductive system |
| 08/01/2002 | WO2002026733A3 sHARMACEUTICALLY ACTIVE SULFONAMIDE DERIVATIVES BEARING BOTH LIPOPHILIC AND IONISABLE MOIETIES AS INHIBITORS OF PROTEIN JUNKINASES |
| 08/01/2002 | WO2002022572A3 Ligands for monoamine receptors and transporters, and methods of use thereof (neurotransmission) |
| 08/01/2002 | WO2002022166A3 Tweak receptor agonists as anti-angiogenic agents |
| 08/01/2002 | WO2002017963A3 Modulators of intermediate conductance calcium-activated potassium (ikca) channel activity for treating sexual dysfunction |
| 08/01/2002 | WO2002016620A3 Modulation of stem cell differentiation |
| 08/01/2002 | WO2002014477A3 Bioavailable composition of natural and synthetic hca |
| 08/01/2002 | WO2002014319A3 Heterocyclic compounds useful as inhibitors of tyrosine kinases |
| 08/01/2002 | WO2002012227A3 Indole, azaindole and indazole derivatives having vegf inhibiting activity |
| 08/01/2002 | WO2002012190A3 Non-imidazole aryloxypiperidines as h3 receptor ligands |
| 08/01/2002 | WO2002011766A3 Use of 5ht4 receptor antagonists in the manufacture of a medicament for the prophylaxis or treatment of atrial fibrillation |
| 08/01/2002 | WO2002008285A3 Il-17 molecules and uses thereof |
| 08/01/2002 | WO2002005794A3 Use of fluorescein derivatives for the treatment of diseases responsive to the activation of the cystic fibrosis transmembrane conductance regulator chloride channel |
| 08/01/2002 | WO2002004019A3 Use of strains of the parapox ovis virus against organ fibrosis |
| 08/01/2002 | WO2002002625A3 Novel fibroblast growth factors and nucleic acids encoding same |
| 08/01/2002 | WO2002002505A3 Compounds to treat alzheimer's disease |
| 08/01/2002 | WO2002000684A3 Method of obtaining peptides with tissue-specific activity and pharmaceutical compositions on their basis |
| 08/01/2002 | WO2001098279A3 Bis-arylsulfones |